PFIZER INC Gain (Loss) on Extinguishment of Debt
PFIZER INC (PFE) reported Gain (Loss) on Extinguishment of Debt of $0 for the 3-month period ending 2020-09-27, per its 10-Q filed 2020-11-05.
Discontinued › Expense Statement › Operating Expenses
us-gaap:GainsLossesOnExtinguishmentOfDebt · last filed 2022-02-24
- PFIZER INC gain (loss) on extinguishment of debt for the quarter ending 2020-09-27 was $0.00.
- PFIZER INC gain (loss) on extinguishment of debt for the quarter ending 2020-06-28 was $0.00.
- PFIZER INC gain (loss) on extinguishment of debt for the quarter ending 2020-03-29 was $0.00.
- PFIZER INC gain (loss) on extinguishment of debt for the quarter ending 2019-12-31 was $0.00.
- PFIZER INC gain (loss) on extinguishment of debt for fiscal 2019 was -$138.00M.
- PFIZER INC gain (loss) on extinguishment of debt for fiscal 2018 was -$3.00M.
- PFIZER INC gain (loss) on extinguishment of debt for fiscal 2017 was -$999.00M.
- PFIZER INC gain (loss) on extinguishment of debt for fiscal 2016 was -$312.00M.
| Period end | Gain (Loss) on Extinguishment of Debt | Gain (Loss) on Extinguishment of Debt 1 month | Gain (Loss) on Extinguishment of Debt 3 month | Gain (Loss) on Extinguishment of Debt 6 month | Gain (Loss) on Extinguishment of Debt 9 month | Gain (Loss) on Extinguishment of Debt 12 month |
|---|---|---|---|---|---|---|
| 2020-09-27 | $0.00 10-Q · filed 2020-11-05 | $0.00 derived: sum of 2 quarters · filed 2020-11-05 | $0.00 10-Q · filed 2020-11-05 | $0.00 derived: sum of 4 quarters · filed 2022-02-24 | ||
| 2020-06-28 | $0.00 10-Q · filed 2020-08-06 | $0.00 10-Q · filed 2020-08-06 | $0.00 derived: sum of 3 quarters · filed 2022-02-24 | $0.00 derived: sum of 4 quarters · filed 2022-02-24 | ||
| 2020-03-29 | $0.00 10-Q · filed 2020-05-07 | $0.00 derived: sum of 2 quarters · filed 2022-02-24 | $0.00 derived: sum of 3 quarters · filed 2022-02-24 | $0.00 derived: sum of 4 quarters · filed 2022-02-24 | ||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $0.00 derived: sum of 2 quarters · filed 2022-02-24 | $0.00 derived: sum of 3 quarters · filed 2022-02-24 | -$138.00M 10-K · filed 2022-02-24 | ||
| 2019-09-29 | $0.00 10-Q · filed 2020-11-05 | $0.00 derived: sum of 2 quarters · filed 2020-11-05 | -$138.00M 10-Q · filed 2020-11-05 | -$138.00M derived: sum of 4 quarters · filed 2020-11-05 | ||
| 2019-06-30 | $0.00 10-Q · filed 2020-08-06 | -$138.00M 10-Q · filed 2020-08-06 | -$138.00M derived: sum of 3 quarters · filed 2020-08-06 | -$138.00M derived: sum of 4 quarters · filed 2020-08-06 | ||
| 2019-03-31 | -$138.00M 10-Q · filed 2020-05-07 | -$138.00M derived: sum of 2 quarters · filed 2020-05-07 | -$138.00M derived: sum of 3 quarters · filed 2020-05-07 | -$138.00M derived: sum of 4 quarters · filed 2020-05-07 | ||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $0.00 derived: sum of 2 quarters · filed 2020-02-27 | $0.00 derived: sum of 3 quarters · filed 2020-02-27 | -$3.00M 10-K · filed 2020-02-27 | ||
| 2018-09-30 | $0.00 10-Q · filed 2019-11-07 | $0.00 derived: sum of 2 quarters · filed 2019-11-07 | -$3.00M 10-Q · filed 2019-11-07 | |||
| 2018-07-01 | $0.00 10-Q · filed 2019-08-08 | -$3.00M 10-Q · filed 2019-08-08 | ||||
| 2018-04-01 | -$3.00M 10-Q · filed 2019-05-09 | |||||
| 2017-12-31 | -$999.00M 10-K · filed 2020-02-27 | -$999.00M 10-K · filed 2020-02-27 | ||||
| 2016-12-31 | -$312.00M 10-K · filed 2019-02-28 | |||||
| 2016-11-30 | -$312.00M 10-K · filed 2019-02-28 | |||||
| 2016-11-21 | -$312.00M 10-K · filed 2017-02-23 | |||||
| 2015-12-31 | $0.00 10-K · filed 2018-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |